{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:13:09Z","timestamp":1781277189345,"version":"3.54.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec id=\"ab-dbr230013-4\"><jats:title>Importance<\/jats:title><jats:p>Older adults with atopic dermatitis (AD) face unique treatment challenges, including comorbidities, polypharmacy, and a higher risk for infections (eg, herpes zoster). Furthermore, limited data are available from clinical trials for treatments in this population. In phase 3 studies, tralokinumab showed superior efficacy in moderate-to-severe AD vs placebo, but results were not stratified by age group.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230013-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the safety and efficacy of tralokinumab in older (\u226565 years) patients with moderate-to-severe AD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230013-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A post hoc analysis for adults 65 years or older was conducted from a subset of patients in the US, Canada, Europe, and Asia in 3 randomized, placebo-controlled, phase 3 trials (ECZTRA 1 and 2 [monotherapy] and ECZTRA 3 [tralokinumab\u2009+\u2009topical corticosteroids as needed]). The post hoc data were analyzed in 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230013-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Pooled data from up to 16 weeks of treatment from ECZTRA 1, 2, and 3 were used to assess safety. Statistical analyses followed prespecifications of primary end points. Separate efficacy analyses were conducted in these trials respectively at 16 weeks.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230013-8\"><jats:title>Results<\/jats:title><jats:p>A total of 75 older adults (42 women [56%]) treated with tralokinumab from the ECZTRA 1, 2, and 3 trials were included in this post hoc analysis. Similar proportions of patients reported adverse events (AEs) with tralokinumab and placebo (44 [58%]). Three patients (4%) in the tralokinumab arm and 3 (10.3%) in the placebo arm experienced severe AEs, and 4 (5.3%) and 2 (6.9%), respectively, had AEs leading to discontinuation. More patients achieved 75% or greater improvement in Eczema Area and Severity Index scores with tralokinumab than placebo (33.9% vs 4.8%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) in ECZTRA 1 and 2. Similar trends, although not statistically significant, were seen in ECZTRA 3. Safety and efficacy outcomes in this population were similar compared with the younger patient cohorts. The small sample size limited generalizations from this analysis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr230013-9\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2626","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T15:33:12Z","timestamp":1692804792000},"page":"1119","source":"Crossref","is-referenced-by-count":24,"title":["Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"159","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mark","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schneider","sequence":"additional","affiliation":[{"name":"LEO Pharma Inc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[{"name":"LEO Pharma Inc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Abuabara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dbr230013r1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.7326\/M18-2246","article-title":"Prevalence of atopic eczema among patients seen in primary care: data from the Health Improvement Network.","volume":"170","author":"Abuabara","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"dbr230013r2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","article-title":"Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review.","volume":"156","author":"Lam","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"dbr230013r3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258219","article-title":"The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom.","volume":"16","author":"Chan","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"dbr230013r4","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/S2666-7568(21)00054-4","article-title":"Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens.","volume":"2","author":"Rochon","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"dbr230013r5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mib.2015.11.003","article-title":"Infection in an aging population.","volume":"29","author":"Kline","year":"2016","journal-title":"Curr Opin Microbiol"},{"key":"dbr230013r6","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"dbr230013r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaad.2019.05.073","article-title":"Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis.","volume":"85","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"dbr230013r8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis.","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dbr230013r9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.v184.3","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"dbr230013r10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.v184.3","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"dbr230013r11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"dbr230013r13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr230013r14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","article-title":"Atopic dermatitis in older adults: a review of treatment options.","volume":"37","author":"Tanei","year":"2020","journal-title":"Drugs Aging"},{"issue":"17","key":"dbr230013r15","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"dbr230013r12","unstructured":"US Food and Drug Administration. Highlights of prescribing information: ADBRY\u2122 (tralokinumab-ldrm) Accessed February 14, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761180Orig1s000lbl.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2808887\/jamadermatology_merola_2023_br_230013_1697555570.33829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T15:08:43Z","timestamp":1697641723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2808887"}},"subtitle":["A Secondary Analysis"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2626","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}